Bing

SEARCH HISTORY

At Stock Options Channel, our YieldBoost formula has looked up and down the VVUS options chain for the new August 21st contracts and identified one put and one call contract of particular interest. The put contract …
The Street · 5/19/2015
Options Trading
Vivus (NASDAQ:VVUS) investors had a bit of something to smile about when ... but it may also be a long time before the equity shows the type of appreciation that can get the stock to $3.00. Stay Tuned!
Seeking Alpha · BySpencer Osborne · 5/20/2015
Zacks upgraded shares of VIVUS (NASDAQ:VVUS) from a hold rating to a buy rating in a research note released on Friday morning. They currently have $2.75 target price on the stock. Zacks’ analyst wrote, “VIVUS’ first quarter results were better-than ...
Mideast Times · 5/10/2015
More from Bing News
Orexigen Therapeutics (NASDAQ: OREX ) has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals (NASDAQ: ARNA ) and VIVUS (NASDAQ: VVUS ) weren't able ... train ready to …
The Motley Fool · ByBrian Orelli · 5/16/2015
MOUNTAIN VIEW, CA--(Marketwired - May 14, 2015) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual …
Financial Content · 5/14/2015
VIVUS
Last month, VVUS shares sank sharply after the company’s stock rating was downgraded by Piper Jaffray. VVUS stock closed at $4.67 per share on Tuesday.
Investor Place · ByChristopher Freeburn · 5/28/2014
Vivus Inc. (VVUS) stock is up over 18% today after the US Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for Stendra. The drug was developed to treat erectile dysfunction (ED) and the recent approval allows for …
bidnessetc.com · 9/19/2014
VIVUS (NASDAQ:VVUS) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm currently has a $2.75 target price on the stock. Zacks‘s target price suggests a potential upside of 13.64% from the ...
Ticker Report · 5/8/2015
Many investors appear to be quite bearish on VIVUS, Inc. (VVUS), especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.97% of the float is sold short, suggesting an extreme level of bearishness for VVUS.
Yahoo Finance · 6/3/2014
Small cap obesity drug stock VIVUS, Inc (NASDAQ: VVUS), who’s potential obesity treatment peers include Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and Orexigen Therapeutics, Inc (NASDAQ: OREX), has …
Smallcap Network · 1/5/2015